Phase I, Randomized, Controlled, Third-party Double-blind, Dose Escalating Study of Protexia Administered Intramuscularly at One or Two Time Points in Healthy Human Volunteers
Latest Information Update: 14 Dec 2022
At a glance
- Drugs Human butyrylcholinesterase (Primary)
- Indications Poisoning
- Focus Adverse reactions
- Sponsors PharmAthene
Most Recent Events
- 23 May 2014 New trial record